{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:13:22Z","timestamp":1762272802112,"version":"3.41.2"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy assessment of human anti\u2010IgE monoclonal antibodies (mAbs) in animal models before clinical trials is hampered due to the lack of cross\u2010reactivity of anti\u2010IgE mAbs between species.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We developed CRE\u2010DR (an anti\u2010dog IgE monoclonal antibody), an anti\u2010IgE mouse mAb that recognizes canine and human IgE, and then examined its IgE specificity and cross\u2010reactivity between three animal and human species.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After mouse immunization with a synthetic peptide derived from canine IgE (<jats:sup>282<\/jats:sup>NTNDWIEGETYYC<jats:sup>294<\/jats:sup>), we generated a hybridoma producing CRE\u2010DR. The CRE\u2010DR purified from the ascites of hybridoma\u2010inoculated mice was used for ELISA and Western blot analysis to examine reactivity to dog, human, and rodent IgEs as well as recombinant bovine serum albumin (BSA)\u2010conjugated to canine, human, and rodent IgE amino acid peptides corresponding to the immunizing sequence. We then performed enzyme\u2010linked immunosorbent assays (ELISAs) for dog IgE using sera from dogs with atopic dermatitis (AD) after inhibition with canine IgE and IgG. The amino acid sequence recognized by CRE\u2010DR was identified by ELISA using synthetic peptides.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CRE\u2010DR is a monoclonal mouse IgG1\u03ba specific for dog IgE, and the ELISA values in atopic dog sera were inhibited by dog IgE, but not dog IgG. The binding of CRE\u2010DR to human IgE was relatively maintained, but not to rodent IgEs, which results were confirmed with the BSA\u2010conjugated IgE peptides of the various species. The CRE\u2010DR reactivity was supported by the comparison of amino acid sequence of CRE\u2010DR epitope, DWIEGETYYC, in dog IgE; one, two, and three amino acids were substituted in the human, rat, and mouse IgE epitopes, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Clinical Relevance<\/jats:title><jats:p>CRE\u2010DR is a mAb cross\u2010reactive to dog and human IgEs, which can allow the use of a dog model of allergy to test the efficacy of a CRE\u2010DR\u2010derived anti\u2010IgE therapeutic mAb before human clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.531","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T05:47:08Z","timestamp":1631857628000},"page":"1740-1748","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and characterization of a unique anti\u2010IgE mouse monoclonal antibody cross\u2010reactive between human and canine IgE"],"prefix":"10.1002","volume":"9","author":[{"given":"Akiko","family":"Kumagai","sequence":"first","affiliation":[{"name":"Animal Allergy Clinical Laboratories Inc.  Sagamihara Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Nara","sequence":"additional","affiliation":[{"name":"Animal Allergy Clinical Laboratories Inc.  Sagamihara Kanagawa Japan"},{"name":"Vaccine Innovation Laboratory, RIKEN Cluster of Science, Technology and Innovation Hub, RIKEN Baton Zone Program, RIKEN Yokohama Institute  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Animal Allergy Clinical Laboratories Inc.  Sagamihara Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kakinuma","sequence":"additional","affiliation":[{"name":"Animal Allergy Clinical Laboratories Inc.  Sagamihara Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[{"name":"Vaccine Innovation Laboratory, RIKEN Cluster of Science, Technology and Innovation Hub, RIKEN Baton Zone Program, RIKEN Yokohama Institute  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-3284","authenticated-orcid":false,"given":"Kenichi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Animal Allergy Clinical Laboratories Inc.  Sagamihara Kanagawa Japan"},{"name":"Vaccine Innovation Laboratory, RIKEN Cluster of Science, Technology and Innovation Hub, RIKEN Baton Zone Program, RIKEN Yokohama Institute  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8707(66)90050-5"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.04.040186.002223"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2007.03.013"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13815-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.08.055"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.07.010"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13Suppl2\/05"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0347-2"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.62.995"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0959-4493.2001.00277.x"},{"issue":"3","key":"e_1_2_10_14_1","first-page":"389","article-title":"Translational animal models of atopic dermatitis for preclinical studies","volume":"90","author":"Martel BC","year":"2017","journal-title":"Yale J Biol Med"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2017.01.022"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(00)00183-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni811"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/35018500"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02741.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2010.09.002"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2019.05.002"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(99)00142-7"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000236569"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142182"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:26:47Z","timestamp":1753943207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/iid3.531"],"URL":"https:\/\/doi.org\/10.1002\/iid3.531","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"type":"print","value":"2050-4527"},{"type":"electronic","value":"2050-4527"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"2021-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}